Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

Anna S. Lok; Fabien Zoulim; Stephen Locarnini; Angeline Bartholomeusz; Marc G. Ghany; Jean Michel Pawlotsky; Yun Fan Liaw; Masashi Mizokami; Carla Kuiken; Rajen Koshy; T. Jake Liang; William Mason

doi:10.1002/hep.21698

Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

Anna S. Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G. Ghany, Jean Michel Pawlotsky, Yun Fan Liaw, Masashi Mizokami, Carla Kuiken, Rajen Koshy, T. Jake Liang, William Mason

Research output: Contribution to journal › Article › peer-review

381 Scopus citations

Abstract

Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

Original language	English (US)
Pages (from-to)	254-265
Number of pages	12
Journal	Hepatology
Volume	46
Issue number	1
DOIs	https://doi.org/10.1002/hep.21698
State	Published - Jul 2007
Externally published	Yes

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.21698

Cite this

@article{0cc1d6fcc761493d8d48e67860a475fd,

title = "Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management",

abstract = "Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.",

author = "Lok, {Anna S.} and Fabien Zoulim and Stephen Locarnini and Angeline Bartholomeusz and Ghany, {Marc G.} and Pawlotsky, {Jean Michel} and Liaw, {Yun Fan} and Masashi Mizokami and Carla Kuiken and Rajen Koshy and Liang, {T. Jake} and William Mason",

year = "2007",

month = jul,

doi = "10.1002/hep.21698",

language = "English (US)",

volume = "46",

pages = "254--265",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Antiviral drug-resistant HBV

T2 - Standardization of nomenclature and assays and recommendations for management

AU - Lok, Anna S.

AU - Zoulim, Fabien

AU - Locarnini, Stephen

AU - Bartholomeusz, Angeline

AU - Ghany, Marc G.

AU - Pawlotsky, Jean Michel

AU - Liaw, Yun Fan

AU - Mizokami, Masashi

AU - Kuiken, Carla

AU - Koshy, Rajen

AU - Liang, T. Jake

AU - Mason, William

PY - 2007/7

Y1 - 2007/7

N2 - Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

AB - Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

UR - http://www.scopus.com/inward/record.url?scp=34547425435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547425435&partnerID=8YFLogxK

U2 - 10.1002/hep.21698

DO - 10.1002/hep.21698

M3 - Article

C2 - 17596850

AN - SCOPUS:34547425435

SN - 0270-9139

VL - 46

SP - 254

EP - 265

JO - Hepatology

JF - Hepatology

IS - 1

ER -

Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this